JP2018534245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534245A5 JP2018534245A5 JP2018513462A JP2018513462A JP2018534245A5 JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5 JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018513462 A JP2018513462 A JP 2018513462A JP 2018534245 A5 JP2018534245 A5 JP 2018534245A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- family
- igsf
- modified
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 29
- 230000003834 intracellular effect Effects 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 230000004957 immunoregulator effect Effects 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- -1 CD86 Proteins 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000011664 signaling Effects 0.000 claims 7
- 102100029740 Poliovirus receptor Human genes 0.000 claims 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 4
- 102000002698 KIR Receptors Human genes 0.000 claims 4
- 108010043610 KIR Receptors Proteins 0.000 claims 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims 4
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 210000004698 lymphocyte Anatomy 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 4
- 102100038077 CD226 antigen Human genes 0.000 claims 3
- 102100034980 ICOS ligand Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 3
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000004555 Butyrophilins Human genes 0.000 claims 2
- 108010017533 Butyrophilins Proteins 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- 101710185679 CD276 antigen Proteins 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 2
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101710093458 ICOS ligand Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 2
- 101150065403 NECTIN2 gene Proteins 0.000 claims 2
- 102000002356 Nectin Human genes 0.000 claims 2
- 108060005251 Nectin Proteins 0.000 claims 2
- 102100035488 Nectin-2 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 2
- 108700010039 chimeric receptor Proteins 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000001976 improved effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 108010048507 poliovirus receptor Proteins 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218531P | 2015-09-14 | 2015-09-14 | |
| US62/218,531 | 2015-09-14 | ||
| US201662323608P | 2016-04-15 | 2016-04-15 | |
| US201662323595P | 2016-04-15 | 2016-04-15 | |
| US62/323,595 | 2016-04-15 | ||
| US62/323,608 | 2016-04-15 | ||
| US201662367822P | 2016-07-28 | 2016-07-28 | |
| US201662367819P | 2016-07-28 | 2016-07-28 | |
| US62/367,822 | 2016-07-28 | ||
| US62/367,819 | 2016-07-28 | ||
| PCT/US2016/051786 WO2017048878A1 (en) | 2015-09-14 | 2016-09-14 | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534245A JP2018534245A (ja) | 2018-11-22 |
| JP2018534245A5 true JP2018534245A5 (https=) | 2019-10-24 |
Family
ID=57068203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513462A Pending JP2018534245A (ja) | 2015-09-14 | 2016-09-14 | 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180256644A1 (https=) |
| EP (1) | EP3350206A1 (https=) |
| JP (1) | JP2018534245A (https=) |
| KR (1) | KR20180054713A (https=) |
| CN (1) | CN108513576A (https=) |
| AU (1) | AU2016323069A1 (https=) |
| BR (1) | BR112018004965A2 (https=) |
| CA (1) | CA2997217A1 (https=) |
| EA (1) | EA201890729A1 (https=) |
| IL (1) | IL258102A (https=) |
| MX (1) | MX2018003144A (https=) |
| WO (1) | WO2017048878A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| US11254744B2 (en) | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| WO2018075978A1 (en) * | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190139216A (ko) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법 |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) * | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| AU2019205273B2 (en) * | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| CA3124721A1 (en) * | 2018-12-24 | 2020-07-02 | Xiaoyi Zhou | Recombinant human 21g-b7-h3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof |
| EP3908372A1 (en) * | 2019-01-13 | 2021-11-17 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Antibodies specific to human nectin-2 |
| US12589132B2 (en) | 2019-02-22 | 2026-03-31 | Five Prime Therapeutics, Inc. | CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors |
| JP7535273B2 (ja) * | 2019-04-26 | 2024-08-16 | スアンズ バイオファーマシューティカル カンパニー，リミテッド | Ｃｄ８０バリアントタンパク質とその使用 |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| CN110859951A (zh) * | 2019-09-23 | 2020-03-06 | 中国药科大学 | Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用 |
| CN113087806B (zh) * | 2019-12-31 | 2022-09-06 | 华东师范大学 | 靶向多种肿瘤的新型car-t细胞及其制备和方法 |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| WO2022170033A1 (en) * | 2021-02-04 | 2022-08-11 | The Trustees Of Dartmouth College | Engineered natural ligand-based car: directed evolution of the stress-receptor nkp30 |
| KR20240152879A (ko) | 2022-02-28 | 2024-10-22 | 넥틴 테라퓨틱스 리미티드 | 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| EP1360290A2 (en) * | 2000-06-23 | 2003-11-12 | Maxygen, Inc. | Co-stimulatory molecules |
| SI2856876T1 (en) * | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| CN103796681B (zh) * | 2011-06-30 | 2018-07-20 | 建新公司 | T细胞活化的抑制剂 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| WO2013169338A1 (en) * | 2012-05-11 | 2013-11-14 | Medimmune, Llc | Ctla-4 variants |
| GB201311475D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| CN121159719A (zh) * | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
-
2016
- 2016-09-14 CN CN201680066217.XA patent/CN108513576A/zh active Pending
- 2016-09-14 US US15/759,812 patent/US20180256644A1/en not_active Abandoned
- 2016-09-14 KR KR1020187010556A patent/KR20180054713A/ko not_active Withdrawn
- 2016-09-14 EA EA201890729A patent/EA201890729A1/ru unknown
- 2016-09-14 WO PCT/US2016/051786 patent/WO2017048878A1/en not_active Ceased
- 2016-09-14 EP EP16775919.0A patent/EP3350206A1/en not_active Withdrawn
- 2016-09-14 AU AU2016323069A patent/AU2016323069A1/en not_active Abandoned
- 2016-09-14 CA CA2997217A patent/CA2997217A1/en not_active Abandoned
- 2016-09-14 MX MX2018003144A patent/MX2018003144A/es unknown
- 2016-09-14 BR BR112018004965A patent/BR112018004965A2/pt not_active IP Right Cessation
- 2016-09-14 JP JP2018513462A patent/JP2018534245A/ja active Pending
-
2018
- 2018-03-13 IL IL258102A patent/IL258102A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534245A5 (https=) | ||
| JP2020500010A5 (https=) | ||
| JP2018508219A5 (https=) | ||
| JP2020511136A5 (https=) | ||
| JP7433348B2 (ja) | キメラポリペプチド及びそれらの細胞膜における局在を変更する方法 | |
| JP2024507996A5 (https=) | ||
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| JP2020114264A5 (https=) | ||
| JP2021514631A5 (https=) | ||
| JP2019531328A5 (https=) | ||
| US20210363218A1 (en) | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof | |
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| JP2017501702A5 (https=) | ||
| JP2018504459A5 (https=) | ||
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| US20220389075A1 (en) | Engineered t cell receptors and uses thereof | |
| KR20180054713A (ko) | 조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법 | |
| NZ759969A (en) | Tagged chimeric effector molecules and receptors thereof | |
| JP2017519502A5 (https=) | ||
| JP2018525006A5 (https=) | ||
| JP2016506761A5 (https=) | ||
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| JP2021501587A (ja) | Ｃｄ３８指向性キメラ抗原受容体構築物 | |
| JP2023519346A5 (https=) | ||
| JP2022515331A5 (https=) |